Circulating cfDNA CD86 methylation is associated with durable response to atezolizumab-bevacizumab in hepatocellular carcinoma
{{output}}
Background: /purpose. Although atezolizumab-bevacizumab is approved for unresectable hepatocellular carcinoma (HCC), only a subset of patients attains a durable response (DR). Non-invasive predictors of long-term benefit are lack... ...
